PureHealth Holding, the Abu Dhabi-listed healthcare group, said net profit rose 14.1% to AED1.8 billion in the first nine months of 2026, according to its results statement published on Friday.
Net profit for the period was AED1.769 billion, according to figures filed on the Abu Dhabi Securities Exchange. Earnings per share were AED0.15.
Revenue increased 11.5% to AED22.4 billion. Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 20.4% to AED4.2 billion, and the EBITDA margin widened to 18.6% from 17.3% a year earlier.
International hospitals led the growth. Revenue from the international care business rose 53% to AED7.3 billion, and its EBITDA climbed 63% to AED1.6 billion.
Hellenic Healthcare Group, which runs hospitals in Greece and Cyprus and was consolidated during the period, contributed AED2.3 billion of revenue. Revenue at Circle Health Group in the UK grew 5.3%. International operations made up about 33% of group revenue.
Reported revenue from the UAE care business fell 9.2% to AED8.7 billion. The company attributed the decline to how revenue from its Unified Purchasing Programme is recognized, internal eliminations and lower patient activity in the first quarter. On a normalized basis, UAE care revenue rose 6% to AED10.1 billion, it said.
UAE outpatient volumes rose 9% and inpatient volumes 13%. Bed occupancy reached 76%, and operational capacity grew to 3,543 beds from 3,433.
Insurance revenue rose 11.7% to AED6.4 billion, and gross written premiums grew 14% to AED6.8 billion. Net profit at Daman, the group’s health insurer, increased 3.9% to AED667 million.
“The integration of Hellenic Healthcare Group has significantly expanded our position in Greece and Cyprus, while the continued development of Circle Health Group is strengthening our presence in the UK,” said Kamal Al Maazmi, chairman of PureHealth.
Shaista Asif, group chief executive officer, said Circle Health Group had agreed to take over selected UK laboratory operations from Unilabs Limited. The company said capital allocation would remain selective, balancing organic investment, acquisitions and shareholder returns.
